Developing Story
ByHeart Infant Formula MDL Consolidation (2026)
The JPML has consolidated 19 class action lawsuits against premium infant formula brand ByHeart into a new MDL in New York federal court, signaling a significant litigation wave against the company. The consolidation will accelerate discovery coordination and settlement pressure on ByHeart.
Importance: 65%Confidence: 82%Mentions: 1Updated: May 1, 2026
## ByHeart Infant Formula MDL Consolidation (2026)
### Overview
The Judicial Panel on Multidistrict Litigation (JPML) has consolidated 19 class action lawsuits filed against ByHeart Inc. into a new multidistrict litigation (MDL) in New York federal court (Top Class Actions, April 2026). ByHeart is a premium infant formula brand that markets itself as using whole proteins and cleaner ingredients.
### MDL Details
- **Number of cases consolidated**: 19 class action lawsuits (Top Class Actions, April 2026)
- **Venue**: New York federal court (Top Class Actions, April 2026)
- **Consolidating body**: Judicial Panel on Multidistrict Litigation (JPML) (Top Class Actions, April 2026)
### Alleged Claims
While the source does not detail specific allegations, infant formula MDLs typically involve claims of:
- Mislabeling or false advertising regarding nutritional content or ingredient quality
- Failure to warn regarding contamination risks
- Breach of warranty
- Consumer protection statute violations (state UDAP claims)
### Legal Significance
MDL consolidation signals that plaintiffs' counsel view the litigation as having sufficient scale and common factual questions to warrant coordinated pre-trial proceedings. The New York venue will subject ByHeart to discovery coordination and likely early bellwether trial selection.
**Comparison**: The infant formula MDL landscape has been active following the Mead Johnson/Abbott NEC (necrotizing enterocolitis) litigation wave. The ByHeart MDL may reflect a distinct theory—likely marketing/labeling rather than NEC—but will benefit from established MDL infrastructure.
### Strategic Significance
- ByHeart's premium market positioning and investor backing make it a high-profile defendant
- MDL consolidation typically accelerates settlement pressure on smaller defendants
- Outcome may affect labeling standards across the premium infant formula market
- Relevant to FDA regulatory posture on infant formula claims post-2022 shortage crisis
### Anticipated Developments
- Appointment of Plaintiffs' Steering Committee
- Initial case management conference and scheduling order
- Motion practice on class certification and Daubert challenges
- Potential early settlement discussions